CDER Vs. CBER: Consulting As Usual, Or Hints Of Inter-Center Power Struggle?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In the Provenge review documents FDA has released so far, there is little indication of overt struggle between the drugs and biologics camps - but many signs that the overheated public and media atmosphere was making the agency especially careful in its dealings with the sponsor.